Associations between FAS rs2234767 and FASL rs763110 polymorphisms and the risk of lung cancer: a meta-analysis of 39,736 subjects
Authors Yu X, Li Y, Yu Y, Lei J, Wan G, Cao F
Received 17 December 2015
Accepted for publication 18 February 2016
Published 6 April 2016 Volume 2016:9 Pages 2049—2056
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Manfred Beleut
Peer reviewer comments 3
Editor who approved publication: Professor Min Li
Xiongjie Yu,1,* Yanli Li,2,* Yuandong Yu,1 Jinhua Lei,1 Guoxing Wan,1 Fengjun Cao1
1Department of Oncology, 2Department of Endocrinology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, People’s Republic of China
*These authors contributed equally to this work
Background: Previous studies have investigated the associations between the common polymorphisms in FAS/FASL genes and lung cancer risk; however, the results remain inconsistent and inconclusive. Hence, we performed a meta-analysis to reassess the relationships between FAS rs2234767 and FASL rs763110 polymorphisms and the risk of lung cancer.
Methods: Eligible studies retrieved by an electronic search were pooled to calculate the strength of the associations using the odds ratio (OR) and 95% confidence interval (95% CI).
Results: A total of 13 case–control studies involving 39,736 subjects (9,237 cases and 10,838 controls on FAS rs2234767 and 8,957 cases and 10,704 controls on FASL rs763110) were included in the meta-analysis. The results showed a significant association between FAS rs2234767 polymorphism and increased risk of lung cancer (A vs G: OR =1.07, 95% CI =1.01–1.13; AA vs GG: OR =1.23, 95% CI =1.06–1.43; AA vs GA + GG: OR =1.24, 95% CI =1.08–1.43). Similar association was also observed in Asian population (AA vs GA + GG: OR =1.30, 95% CI =1.01–1.67) and in the studies with large sample size (A vs G: OR =1.07, 95% CI =1.00–1.14; AA vs GG: OR =1.30, 95% CI =1.07–1.58). However, no significant association between FASL rs763110 polymorphism and lung cancer risk was found other than in the Asian population (CC vs TC + TT: OR =1.35, 95% CI =1.01–1.80).
Conclusion: The meta-analysis indicated that FAS rs2234767 polymorphism was significantly associated with an increased risk of lung cancer and FASL rs763110 polymorphism may not contribute to susceptibility to lung cancer other than in Asian population.
Keywords: FAS, FAS ligand, polymorphism, lung cancer, meta-analysis, risk, apoptosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]